Advances in psychopharmacology have produced medications with substantial efficacy in the treatment of positive and negative symptoms of schizophrenia and the prevention of relapse or symptom exacerbation after an acute episode. In the clinical setting, the individual patient's acceptance or rejection of prescribed pharmacological regimens is often the single greatest determinant of these treatments' effectiveness. For this reason, an understanding of factors that impede and promote patient collaboration with prescribed acute and maintenance treatment should inform both pharmacological and psychosocial treatment planning. We review the substantive literature on medication adherence in schizophrenia and describe a modified health belief model within which empirical findings can be understood. In addition to factors intrinsic to schizophrenia psychopathology, medication-related factors, available social support, substance abuse comorbidity, and the quality of the therapeutic alliance each affect adherence and offer potential points of intervention to improve the likelihood of collaboration. Because noncompliance as a clinical problem is multidetermined, an individualized approach to assessment and treatment, which is often best developed in the context of an ongoing physician-patient relationship, is optimal. The differential diagnosis of noncompliance should lead to interventions that target specific causal factors thought to be operative in the individual patient Schizophrenia Bulletin, 23(4):637-651,1997.
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Although advances in psychopharmacology have vastly improved the range of treatment options for schizophrenia, outcome variance explained by the choice of medication is likely small compared with that accounted for by how and if the patient takes what is prescribed.
Compliance is defined as "the extent to which a person's behavior coincides with medical or health advice" (Haynes 1979, p. 2) . The term has been criticized for over 20 years as a reflection of an outmoded and paternalistic conception of the physician-patient relationship (Stimson 1974; Holm 1993) . Nonetheless, compliance is a word often used in clinical settings where for clinicians, patients, and families it remains one of the most vexing challenges in psychopharmacology.
Compliance is difficult to quantify and study for several reasons. Clinicians' ability to identify which patients do not take medicine is limited (McClellan and Cowan 1970; Norell 1981) . Other measures of adherence include patient or relative self-report, prescription renewals and pill counts, saliva and urine screens, or steady-state serum determinations. Concordance across different measures of compliance is often low, although self-reported noncompliance is corroborated more often than is self-reported adherence (Rickels and Briscoe 1970; Gordis 1976; Boczkowski et al. 1985) . Measurement is further complicated because compliance is rarely an all-or-none phenomenon, but may include errors of omission, mistakes in dosage and timing, and taking medications that are not prescribed (Blackwell 1976) .
A 1986 review of 26 studies using a variety of definitions and detection methods to assess medication use among outpatients with schizophrenia reported a median default rate of 41 percent (range, 10% to 76%) with oral medications and 25 percent (range, 14% to 36%) with depot injections over time periods up to 1 year (Young et al. 1986 ). Fifteen subsequent studies using varying definitions of noncompliance and many mixing patients taking oral and depot medications reported a median 1-month to 2-year noncompliance rate of 55 percent (range, 24% to 88%) (Hogan et al. 1983; Ayers et al. 1984; Carman et al. 1984; Boczkowski et al. 1985; Gaebel and Pietzcker 1985; Munetz and Roth 1985; Frank and Gunderson 1990; Kelly and Scott 1990; Pristach and Smith 1990; Buchanan 1992; Adams and Howe 1993; Parker and Hadzi-Pavlovic 1995; Razali and Yahya 1995; Macpherson et al. 1996a, 19966; Owen et al. 1996) .
The belief that noncompliance is a direct result of disease processes in schizophrenia dominates the clinical perception of noncompliance for these patients. Reported noncompliance rates for schizophrenia, however, are in the middle range of those reported for other common medical disorders. Medication noncompliance rates of 55 to 71 percent have been reported for patients with arthritis (Berg et al. 1993 ), 54 to 82 percent for patients with seizure disorders (Shope 1988) , 20 to 57 percent for patients with bipolar affective disorder (Elixhauser et al. 1990) , and 19 to 80 percent for patients with diabetes (Friedman 1988) . Half of patients with hypertension drop out of care within 1 year, and only two-thirds of those who remain take adequate medication (Eraker et al. 1984) .
A review of compliance with maintenance regimens-rheumatic fever prophylaxis, glaucoma, isoniazid for tuberculosis, and self-administered insulin-found a mean noncompliance rate for these long-term illnesses of 54 percent (Sacket 1976) . Compliance is lowest when the condition is prolonged, treatment is prophylactic or suppressive, and the consequences of stopping treatment are delayed. In disorders sharing these features, adherence declines with time (Blackwell 1973) .
Through 1994 at least 14,000 English-language articles have addressed compliance-related issues in medical care (Donovan 1995) . Recent reviews converge in concluding that noncompliance is far better documented than understood and that a focus on the patient's decisionmaking process is often a key missing ingredient in extant research (Trostle 1988; Morris and Schulz 1993; Donovan 1995) . Health belief (Becker and Maiman 1975; Kirscht and Rosenstock 1979) or health decision (Eraker et al. 1984 ) models that emphasize a patient's subjective assessment of the risks and benefits of treatment in the context of personal values and goals are advanced as best integrating available data on compliance research. Although these models may require modification in disorders like schizophrenia in which cognition and motivation are affected directly by illness processes (Babiker 1986; Bebbington 1995) , they do facilitate a shift in perspective: rather than viewing noncompliance as the patient's problem, it is redefined as an indication that the therapeutic regimen is not assisting the individual patient to achieve his or her goals.
In this article, we review the substantive literature on medication compliance in schizophrenia with an emphasis on empirical studies that (1) identify current or predictive correlates of adherence and noncompliance and (2) assess interventions targeted to improve adherence. These findings provide an empirical basis for the differential diagnosis and understanding of noncompliance within a modified health belief or health decision model.
Methods
This review is limited to studies of medication adherence in schizophrenia: studies focused on psychiatric patients without specifying diagnosis and those focused on adherence to other aspects of treatment, such as aftercare appointments, were not included. Clinical correlates of compliance that have been studied include patient sociodemographic features; illness characteristics, including comorbidity and insight; medication features, including side effects and route and frequency of administration; family and social support; and treatment system characteristics, including quality of the physician-patient relationship. Interventions studied include reinforcement, education, skills training, and memory enhancement.
Potentially relevant English-language articles were identified from the English language psychiatric and psychological literature with the aid of computer searches using such key words as compliance, adherence, psychopharmacology, and schizophrenia. Bibliographies from primary sources and reviews were then reviewed to identify earlier relevant works. In addition to empirical studies (those including some measure of compliance or intention to comply), clinical reports were included for review if they presented useful perspectives on social or psychodynamic issues that would generally be inaccessible to empirical study. In selecting studies for review, reliability testing and corroboration of patient self-report were not required criteria; had they been, very few studies would be left for review. Owen et al. 1996) . Eight of ten found no association with age, six of nine found no association with gender, four of five found no association with ethnicity, and four of four no association with education or income. In contrast, two studies found noncompliance associated with youth, three with male gender, one with single marital status, and one with African-Caribbean ethnicity.
Illness Characteristics.
Illness history. Studies have failed to reveal an association between compliance and age at onset and duration of illness (Buchanan 1992) , age at first hospitalization (McEvoy et al. 1984) , and premorbid functioning (Adams and Howe 1993) . Data relating the number of prior hospitalizations to compliance are contradictory: Three studies indicated more prior hospitalizations (Nelson et al. 1975; Pan and Tantam 1989; Sellwood and Tarrier 1994) ; two studies, fewer prior hospitalizations (Reilly et al. 1967; McEvoy et al. 1984) ; and one study, no difference in prior hospitalizations (Hogan et al. 1983) among patients judged to be noncompliant at an index assessment. Although these data do not strongly support the contention that patients learn to adhere to medications after repeated relapses, hospitalization may improve compliance in the period immediately after discharge: Two studies assessing compliance among patients before and after an index admission showed significant decreases in noncompliance rates at followup (Christensen 1974; Owen et al. 1996) .
The association between compliance and future hospitalization risk is far less equivocal: Seven studies indicated that patients rated as noncompliant have a 6-month to 2-year risk of relapse that is an average of 3.7 times greater than patients rated as compliant (Leff and Wing 1971; Linn et al. 1982; Gaebel and Pietzcker 1985; Munetz and Roth 1985; Kashner et al. 1991; McFarlane et al. 1995; Parker and Hadzi-Pavlovic 1995) . Two additional studies did not allow calculation of relative risk, but identified irregular medication adherence as a significant predictor of relapse (Falloon et al. 1978; Verghese et al. 1989) . The magnitude of elevated risk associated with noncompliance seems comparable with that conveyed by randomization to placebo in maintenance trials (Baldessarini et al. 1990 ). Consistent with these data is the finding of recent medication noncompliance in the history of 38 to 68 percent of relapsed patients (Reilly et al. 1967; Christensen 1974; Herz and Melville 1980; del Campo et al. 1983; Parker and Hadzi-Pavlovic 1995; Owen et al. 1996) . Because relapse typically occurs weeks to months after the discontinuation of medication, however, patients only rarely attribute it to noncompliance (Chien 1975; Herz and Melville 1980) . Although the association between noncompliance and relapse is robust, causality is likely bidirectional: Crawford and Forrest (1974) found erratic pill-taking associated with worsening symptoms for patients taking placebo tablets while maintained on depot phenothiazine injections. Likewise, in a study that randomized schizophrenia patients to drug or placebo groups 2 months after hospital discharge, Hogarty et al. (1973) found that about 50 percent of the relapsers from either group were noncompliant compared with only 15 percent of patients from either group who had not relapsed within 6 months.
Illness severity and subtype. Both inpatient drug refusal and outpatient noncompliance are consistently associated with more severe ratings of psychopathology. Eight studies assessed the relationship between symptom severity or global functioning and inpatient medication refusal, future outpatient medication compliance, or attitude toward medication. Marder et al. (1983) found more severe psychopathology, including disorganization, hostility, and suspiciousness, associated with inpatient drug refusal. Five investigations reported a positive association between symptom severity at or after discharge and poor outpatient compliance (Renton et al. 1963; Van Putten et al. 1976; Kelly et al. 1987; Pan and Tantam 1989) or poor attitude toward compliance (Draine and Solomon 1994) . One study found only the Brief Psychiatric Rating Scale (Overall and Gorham 1962 ) grandiosity score to be associated with poor compliance (Bartko et al. 1988) , and one study reported no relationship between symptom severity at discharge and future outpatient compliance (Ayers et al. 1984) .
Seven studies investigating the relationship between paranoid suspiciousness, persecutory delusions, or schizophrenia subtype and medication adherence yielded mixed results. Two studies reported that noncompliance preceding a hospitalization is more common among patients with paranoid schizophrenia subtype (Reilly et al. 1967; Pristach and Smith 1990 ). An additional investigation reported greater noncompliance as measured with urine screens among inpatients with paranoid delusions (Wilson and Enoch 1967) . In contrast, one investigation found no association between paranoid schizophrenia subtype and the expressed willingness to take medications (Soskis 1978) , one study found no association between subtype and self-reported outpatient compliance (Hoffman et al. 1974) , and another study reported no association between paranoid ratings and missed depot appointments (Bartko et al. 1988) . In a study that may reconcile these discrepant findings, Van Putten et al. (1976) found no association between compliance and paranoid schizophrenia subtype, but noted that 85 percent of paranoid schizophrenia patients with delusions of persecution or influence habitually complied with medications, whereas 92 percent of paranoid patients with grandiose delusions habitually refused medications.
Cognition/memory. Neither overall intelligence (Adams and Howe 1993) , discharge Mini-Mental State Exam score (Folstein et al. 1975; Buchanan 1992) , nor Neurobehavioral Cognitive Status Exam results (Northern California Neurobehavioral Group 1988; Cuffel et al. 1996) has been associated with compliance. The potential association between specific neuropsychological deficits and compliance has not been explored. A significant percentage of outpatients, however, attribute noncompliance to forgetting (Hoffman et al. 1974) or indicate that they believe reminders to take their medicine would be helpful (Serban and Thomas 1974) .
Insight. The concept of insight has undergone considerable elaboration in recent years, coincident with a shift in explanatory focus from psychological to neurologically based formulations of self-awareness deficits (Amador et al. 1993 (Amador et al. , 1994 . A review emphasized the multidimensional nature of insight and its relative independence from symptom severity (Amador et al. 1991) . Using a variety of self-report measures of illness awareness, nine studies assessed the relationship between insight and adherence with prescribed pharmacological regimens. Poor insight was consistently associated with noncompliance. Three studies reported an association between poor insight assessed at admission or during hospitalization and medication noncompliance among inpatients (Lin et al. 1979; Marder et al. 1983; McEvoy et al. 1989) . Four studies reported an association between a lack of insight at hospital admission, discharge, or postdischarge assessment and poor outpatient compliance (Nelson et al. 1975; Van Putten et al. 1976; Bartko et al. 1988; Macpherson et al. 1996a Macpherson et al. , 1996b . Perhaps reflecting the fact that both insight and compliance can fluctuate with clinical state, one study found that an awareness of illness and medication compliance were related only when measured concurrently . One study reported an association between involuntary admission status (an indirect index of insight) and poor 2-year postdischarge medication compliance, but no association between ratings from attitude questionnaires and compliance (Buchanan 1992) . Although a statistical relationship between insight and adherence has been replicated in a variety of settings, several investigators noted that a sizable subgroup of patients who do not believe they are ill or require medication nonetheless are regularly compliant.
Other Health Beliefs. Except for the consistent relationship between awareness of the presence of a psychiatric illness and medication compliance, the association between specific health beliefs and medication compliance among patients with schizophrenia is more ambiguous. Kelly et al. (1987) found that greater perceived susceptibility to rehospitalization was associated with increased compliance among a population made up largely of patients with schizophrenia. Hogan et al. (1983) also found that schizophrenia outpatients rated by their therapists as generally compliant with medication were more likely than noncompliant patients to believe that staying on medication would prevent relapse. Noncompliant patients were more likely to believe that medication should only be taken when one feels sick, that it would harm them physically, and that it is unnatural to take medication. In contrast, Pan and Tantam (1989) found no difference in beliefs about the possibility of relapse if maintenance treatment were stopped between regular attenders and outpatients who had missed two or more appointments over 12 months at a depot neuroleptic clinic. Buchanan (1992) found no association between compliance and self-appraisal of the likelihood of becoming ill again. Serban and Thomas (1974) found that most hospitalized schizophrenia patients who reported that they did not use prescribed medications between hospitalizations failed to do so despite their expressed belief that regular medication would be helpful. It should be noted that this disjunction between health beliefs and behaviors is by no means unique to schizophrenia.
Subjective Weil-Being. Perceived immediate benefit and a subjective sense of well-being derived from medications seem to be associated more consistently with compliance than are expressed beliefs concerning susceptibility to relapse. Patients who do not comply are likely to feel that their medications do not help, are of no benefit, or are ineffective and unnecessary (Nelson et al. 1975; Soskis 1978; Lin et al. 1979; Herz and Melville 1980) . Patients who consent to and comply with neuroleptics are more likely to report feeling better (Marder et al. 1983) , getting help (Buchanan 1992) , and endorsing a direct (Hogan et al. 1983; Razali and Yahya 1995) or indirect (Adams and Howe 1993 ) beneficial effect of medication on their well-being. After resolution of an acute episode, however, some patients stop medications because they feel well and therefore no longer in need of treatment (Reilly et al. 1967; Hoffman et al. 1974) . As described below in the section on side effects, to the extent that subjective well-being is associated with initial and long-term adherence, subjective discomfort is associated with medication refusal or noncompliance.
Co-Occurring Alcohol and Drug Use. Comorbid alcohol or other substance abuse is common among individuals with schizophrenia (Regier et al. 1990 ) and is a strong predictor of neuroleptic noncompliance. Drake et al. (1989) studied 115 outpatients with schizophrenia and found that 45 percent were occasional and 23 percent heavy alcohol users. More severe alcohol use and abuse were associated with medication noncompliance, psychosocial problems (including homelessness), disorganized and hostile behavior, medical problems, and frequent rehospitalizations over a 1-year followup. In a second group of outpatients, Kashner et al. (1991) found that substance-abusing patients with schizophrenia were 13 times more likely than non-substance-abusing patients to be noncompliant with antipsychotic medication. In a group of schizophrenia inpatients with a rate of selfreported noncompliance (72%) before admission that was too high to find an overall association with their substance abuse history, Pristach and Smith (1990) reported that 62 percent stopped taking medications while drinking. Patients often cited their physicians' advice not to mix medicine and alcohol as a reason for intermittent noncompliance. Among inpatients assessed for substance abuse and followed after discharge for 6 months, Owen et al. (1996) reported that substance abuse in the 30 days before index assessment was the strongest predictor of noncompliance at followup assessment. Substance abuse increased the risk of noncompliance eightfold and seemed to interact with decreased outpatient contact to result in poor clinical outcome. Of potential relevance to compliance are reports that tardive dyskinesia and akathisia may be more prevalent among patients who abuse alcohol (Lutz 1976; Olivera et al. 1990; Dixon et al. 1992 ).
Medication-Related Factors.
Side effects. Neuroleptic side effects that may be particularly unpleasant include sedation, anticholinergic effects, cognitive blunting, depression, sexual dysfunction, and extrapyramidal syndromes-dystonia, akinesia, Parkinsonian effects, akathisia, and tardive dyskinesia (Weiden et al. 1986 ). Between one-quarter and two-thirds of patients who unilaterally discontinue prescribed neuroleptic medicines cite side effects as their primary reason for noncompliance (Renton et al. 1963; Reilly et al. 1967; Hoffman et al. 1974; del Campo et al. 1983) . Among outpatients, both self (Falloon et al. 1978; Hogan et al. 1983; Kelly et al. 1987 ) and physician (Nelson et al. 1975; Pan and Tantam 1989; Buchanan 1992 ) ratings of side effects are associated with or predictive of noncompliance.
Although side effects are consistently associated with poor maintenance adherence among outpatients, inpatients may not reliably report a history of side effects. Pristach and Smith (1990) did not find self-reported history of neuroleptic side effects to be related to noncompliance among inpatients before admission. Marder et al. (1983) found no overall association between the selfreported history of side effects and inpatient drug refusal: Inpatient drug refusers were described as including a subgroup of patients with severe side effects and a second group in whom illness-related factors, such as denial, hostility, and grandiosity, were major determinants of refusal. Fleischhacker et al. (1994) attributed their failure to find an association between side effects during the first 4 weeks of treatment and subsequent compliance among patients on haloperidol and clozapine to an aggressive approach to detect and treat adverse effects by changing medications, lowering dosages, and prescribing concomitant medications.
In an important series of studies based on the observation that normal volunteers differed in their reactions to a test dose of phenothiazines (Heninger et al. 1965) , Van Putten et al. (1974) described a subgroup of schizophrenia patients who experienced a dysphoric response to a variety of conventional neuroleptics available at that time. These patients felt miserable on neuroleptics, complained about drug effects, and pleaded to have their medications stopped or dosages reduced. In contrast, nondysphoric responders reported that they "liked" medications and "felt better" on them. Akathisia was found to be the most significant factor underlying a dysphoric neuroleptic response and was highly associated with medication refusal or outpatient noncompliance or both. In some patients, akathisia was experienced as a catastrophic sense of terror and impending annihilation that was phenomenologically similar to an exacerbation of psychosis (Van Putten 1974) . More frequently, patients reported a subtle inner restlessness, anxiety, and inability to feel comfortable in any position, a phenomenon that was incompatible with any productive activities and could not be tolerated for any period of time. However, much of the akathisia responsible for outpatient noncompliance was described as sufficiently mild as to remain undetected by an observer who lacked a close and continuous relationship with the patient (Van Putten 1974) . Two subsequent studies replicated the finding of a significant association between an initial dysphoric response to a test dose of thiothixene or haloperidol, akathisia, and subsequent medication noncompliance (Van Putten et al. 1981 . In a third independent sample, a greater proportion of patients with a dysphoric than a syntonic response to a chlorpromazine test dose were noncompliant over a 9-month followup period (Ayers et al. 1984) . Together, these results point to a strong association among a dysphoric response to medication, akathisia, and medication refusal or noncompliance or both.
Dosage and agent Higher (Pan and Tantam 1989) , lower (Nelson et al. 1975) , and no different (Hogan et al. 1983 ) neuroleptic dosages have been reported among outpatients rated as less compliant with maintenance treat-ment. A curvilinear relationship between dosage and compliance, with very low doses associated with lack of efficacy and very high doses with excessive side effects, seems likely. However, few data are available that assess differential compliance rates to different agents. Carman et al. (1984) found noncompliance rates as measured by serum and urine assays to be significantly higher among patients taking high-potency compared with low-potency agents (65% vs. 13%). Among outpatients receiving phenothiazine injections, Carney and Sheffield (1976) reported a higher noncompliance rate (43%) among those receiving fluphenazine enanthate than among patients receiving fluphenazine decanoate or flupenthixol decanoate (23%). The difference was attributed to a higher rate of extrapyramidal side effects among those prescribed fluphenazine enanthate. We were unable to locate any randomized controlled study assessing compliance with different agents.
The correlation between greater psychopathology at index assessment and noncompliance likely reflects an association between the efficacy of prescribed treatment and compliance. The finding that noncompliance rates for chlorpromazine were substantially higher than those for imipramine among depressed (70% vs. 44%) but not schizophrenia (32% vs. 25%) outpatients provides additional support for a relationship between efficacy and compliance (Willcox et al. 1965) .
Route. A 1986 review of 26 studies reporting noncompliance rates indicated a lower mean default rate (25%) in studies of depot compared with oral (41%) neuroleptics (Young et al. 1986 ). Based on the hypothesized advantage of depot preparations in improving compliance, six controlled studies comparing relapse rates among patients randomized to oral versus depot neuroleptics were reviewed more recently (Davis et al. 1993) . These studies suggest a modest advantage for the depot route in reducing relapse rates that may be greater in nonresearch samples (Dixon et al. 1995) . Changing patients to depot preparations does not, however, seem to be an effective global strategy to eliminate noncompliance: Van Putten et al. (1976) found that 83 percent of habitually noncompliant schizophrenia outpatients who were switched to decanoate did not return with any regularity for bimonthly injections. Likewise, Falloon et al. (1978) reported that 73 percent of schizophrenia patients returned to the community after hospital treatment who were irregular in their tablet taking also missed at least one injection in 12 months. Buchanan (1992) found no difference in compliance rates over 2 years postdischarge for patients taking oral and depot neuroleptics.
Although long-acting phenothiazine injections do not ensure medication compliance because they must be administered by a treatment provider, noncompliance with this type of treatment can be detected quickly and with certainty. Such noncompliance allows an assessment of clinical impact for the individual patient and may trigger assertive interventions. For this reason, the major advantage of depot neuroleptics may be the ability to eliminate covert noncompliance as a cause of clinical decompensation (Schooler and Keith 1993) .
Complexity of regimen. Although the complexity of a medication regimen is associated with compliance across a broad range of medical disorders (Haynes 1976) , only one (Razali and Yahya 1995) of four empirical studies that focused exclusively on schizophrenia identified a statistically significant association between complexity of regimen and compliance. Hoffman et al. (1974) , Hogan et al. (1983) , and Buchanan (1992) found no such association.
Environmental Factors.
Family and social support. Social support, in general, and the availability of family or friends to assist or supervise medications, in particular, are consistently associated with outpatient adherence. Eight studies indicated that patients living with relatives or whose medications are supervised by relatives are more likely than those lacking such support to maintain adherence to prescribed antipsychotic medication (Parkes et al. 1962; Renton et al. 1963; Reilly et al. 1967; Hoffman et al. 1974; Nelson et al. 1975; Van Putten et al. 1976; Buchanan 1992; Razali and Yahya 1995) . An additional study found a nonsignificant association between stability of living arrangements and compliance . Causality is likely bidirectional in determining the association between family or social support and compliance. In a group of mostly schizophrenia outpatients, Draine and Solomon (1994) found that better social functioning and more extensive social networks were related to positive attitudes toward medication compliance. In addition, negative or stressful social interactions may counteract the positive effect on compliance of living with others (Reilly et al. 1967) .
Practical barriers. In one investigation, 28 percent of patients who had reduced or stopped taking medications before an inpatient admission cited financial burden as the principal reason for discontinuation (Reilly et al. 1967) . Sullivan et al. (1995) found that family informants reported that 7 percent of previously hospitalized patients lacked money for medication and 19 percent had missed medication because of a lack of transportation to the pharmacy. Practical barriers or lack of access to care may be particularly salient for homeless individuals, who are often viewed as noncompliant (Interagency Council on the Homeless 1992).
Physician-patient relationship.
The clinical supposition that a positive therapeutic alliance facilitates medication compliance finds empirical support in three studies. Nelson et al. (1975) found that the single best predictor of medication compliance among discharged schizophrenia patients was the patient's perception of the physician's interest in him or her as a person. Marder et al. (1983) found that, compared with patients who refused medications, schizophrenia inpatients who consented to neuroleptic treatment rated themselves as more satisfied with ward staff and their own physicians and felt that their physicians understood them, had their best interests in mind, and had explained the reasons for taking medications and their potential side effects. Illness severity or treatment response may partially explain these associations. Frank and Gunderson (1990) found that 74 percent of patients with fair or poor therapeutic alliances (rated at 6 months) failed to comply fully with prescribed medication regimens during the next year and a half. In contrast, only 26 percent of schizophrenia patients with a good alliance with their therapist (rated at 6 months) were noncompliant. In this study, the association between therapeutic alliance and medication compliance was independent of the patient's severity of psychopathology, type or dosage of medication, or inpatient/outpatient status.
Attitude of staff. Irwin et al. (1971) reported a nonsignificantly higher noncompliance rate as determined by urine screen (39% vs. 25%) among outpatients treated by physicians who viewed medication as having questionable value, compared with patients of physicians who viewed medication as an essential aspect of treatment.
Interventions. Psychosocial treatments for schizophrenia often include promotion of medication compliance as an implicit or explicit goal. Data bearing on the efficacy of individual psychotherapy, social skills training, case management, family psychoeducation, and assertive community treatment programs have been reviewed recently . Here we review a more narrow set of interventions that specifically target medication compliance: reinforcement, education, and memory enhancement.
Reinforcement. When characterized by institutional surroundings, long waits, and impersonal or bureaucratic treatment, mental health clinics can be uninviting in a way that discourages attendance and compliance (Talbott et al. 1986; Chen 1991; Dencker and Liberman 1995) . Making the setting more appealing by providing reinforcement has improved adherence. Liberman and Davis (1975) designed a program to reinforce compliance by serving lunch at a monthly medication clinic and allowing patients who tested positive for neuroleptics to select among several rewards, including toiletries and personal items. Compared with patients randomly assigned to a control medication group, the experimental group showed better attendance, higher compliance levels, and more positive attitudes toward medication. Cassino et al. (1987) successfully increased attendance among schizophrenia patients at a decanoate clinic from 58 to 76 percent over a 17-week period by offering brunch at morning sessions of the clinic. Offering lunch-type food at an afternoon session, however, had little effect on attendance.
Education. Circumscribed educational interventions aimed at providing information about schizophrenia and its treatment have been ineffective at increasing compliance. Boczkowski et al. (1985) found no difference in compliance between an experimental group of outpatients provided a 30-to 50-minute information session and a control group for whom no specific attempt to focus on medication or diagnosis was made. Macpherson et al. (1996a) randomly assigned patients to one of three groups: one receiving three educational sessions at weekly intervals, one receiving a single educational session, and one having no educational intervention. Although participants in the group receiving the three sessions did have fewer knowledge errors at 1-month followup, their scores on a medication compliance scale did not change. Similarly, Brown et al. (1987) documented an increase in knowledge among schizophrenia outpatients who received two instructional sessions 1 month apart, but noted that instruction did not affect independently rated compliance.
Skills training in areas related to medication seems to be more effective than providing factual information. Eckman et al. (1990) designed a medication management module that trained patients in four skill areas: obtaining information about medications, administering medication and evaluating its benefits, identifying side effects, and negotiating medication with health care providers. The module was delivered to patients in a variety of settings for 3 hours per week over 15 to 20 weeks. Upon completion of the module and over a 3-month followup, knowledge about medication, skill utilization, and compliance improved over baseline. Compliance assessed by the patients' psychiatrists increased from 67 percent before training to 82 percent after training, and compliance assessed by designated caregivers increased from 60 to 79 percent.
Based on a randomized trial of individual and family education, Kelly and Scott (1990) described two circumscribed interventions that each reduced noncompliance at 6-month followup. The individual intervention was delivered by a health educator before the first two postdischarge aftercare appointments and focused on increasing the patient's ability to communicate with providers by expressing concerns and asking questions. The family intervention included up to three home visits that focused on the development of an individualized behaviorally oriented compliance plan that, if necessary, included family involvement in aftercare. The authors believed that the critical ingredients in each of these effective interventions were frequent repetition and behavioral modeling, rather than appealing to attitudes and beliefs. Skills training of this sort was described as least effective for patients with comorbid alcoholism, who frequently dropped out of treatment. Nelson et al. (1975) reported that a basic form of skills training-allowing schizophrenia patients to selfadminister medications while hospitalized-increased outpatient compliance over a 6-to 24-week followup. The intervention was effective, however, only for patients who, based on Rorschach test data, accepted that they were psychiatrically disturbed.
In a study of the impact of psychoeducationally oriented family therapy on medication compliance, Strang et al. (1981) randomly assigned to individual supportive or family therapy recently discharged schizophrenia patients living with a relative who exhibited high expressed emotion. Patients receiving family therapy that included specific behavioral compliance strategies worked out between patient and family were more likely to take their prescribed tablets, less likely to require a change to depot neuroleptics, and showed higher and more stable neuroleptic plasma levels, despite identical mean daily doses for the two groups.
Memory enhancement. Boczkowski et al. (1985) described a "behavioral tailoring" intervention that included identifying a highly visible location for storing medication, pairing medication intake with specific routine behaviors, and prescribing a self-monitoring calendar with tear-off slips. In a randomized trial, behavioral training participants were more compliant at 1-and 3-month followup than patients receiving a didactic educational session or control intervention.
Psychodynamic Considerations. Data concerning the role of psychodynamic factors in medication compliance derive from the observations of clinicians prescribing medication to patients with schizophrenia over time. Three areas are consistently identified as pertinent: the psychological meaning of medication to the individual patient, the role of psychotic symptoms in maintaining self-esteem or personality organization, and issues related to transference and countertransference.
Psychological meaning. Clinicians have reported a wide range of psychological meanings ascribed to medications. Patients who are preoccupied with issues of authority and control may be particularly prone to engage in struggles over medication (Amdur 1979) . In view of the significant loss of personal control associated with psychosis, Diamond (1984) described noncompliance as an effort to regain control over one's life and feel better. Gutheil (1977) noted that individual patients may concretely equate medication with sickness ("/// need drugs I must be sick. The higher the dose the sicker I am. I'll stop being sick if I stop taking drugs"). Book (1987) described several dynamic issues affecting compliance: paranoid patients' experience of being controlled, poisoned, or invaded by medication; the painful reminder of a defective, "about to fall apart" self among patients who make extensive use of denial; and the possibility that patients' attitudes toward medication are influenced by identification with relatives who received similar medication and experienced poor outcomes, such as suicide.
While viewing compliance primarily as a learned behavioral response, Falloon (1984) noted that some patients fear that prolonged medication may lead to dependence and addiction or equate the need for medication with having a weak character. Taking medication may also be equated with physical or psychological weakness so that the recovering patient who feels strong enough will stop taking medicine (Amdur 1979) . Noncompliance in this context may be a test or gamble designed to determine if the illness is still present (Morris and Schulz 1993) .
Medication may be be an area around which family or interpersonal conflicts are enacted, so patients stop medication to express anger toward a relative or mental health professional (Kane 1983) . Similarly, patients may discontinue medications in the face of increased pressure to improve functioning or on the verge of hospital discharge or beginning a new job, school, or rehabilitation program. In these circumstances noncompliance can be understood as an unconscious expression of the fear of autonomy or as a communication that expectations have been set too high (Fenton and McGlashan 1995) .
Psychological homeostasis. Psychotic symptoms may be syntonic or serve to support an individual against further personality disintegration or the collapse of selfesteem. Grandiose delusions cast the self as powerful, and persecutory delusions mark the sufferer as worthy of special persecution. When psychosis provides a more positive self-image than can be provided by reality, patients will cling tenaciously to delusions and resist efforts to ameliorate them (Van Putten et al. 1976; Corrigan et al. 1990) . Under these circumstances a frontal attack on psychotic symptoms is rarely effective and may precipitate a catastrophic collapse in self-esteem that leads to selfdestructive behavior (Drake and Sederer 1986) . Some patients, particularly young men, who organize a sense of self-cohesion around body well-being and activity may experience the physical effect of neuroleptics as a threat to self-organization (Heninger et al. 1965) . Other patients may adapt to impending personality disorganization by globally organizing in opposition to the will of others and may resist medications as part of an overall effort to maintain a tenuous sense of effectiveness or control.
Transference/countertransference. Clinicians have noted that patients' views of medications arise in relation to their attitude toward the prescriber and may be distorted by these attitudes. In the context of a relationship perceived as authoritarian, the physical effects of medication may be perceived as rejecting, hostile, or threatening (Sarwer-Foner 1960) or as a bodily attack or invasion (Gutheil 1977) . Other interpretations may cast the prescription as a negative dismissal of the patient, or the patient may fear that the reduction of symptoms will be accompanied by a parallel reduction in the physician's interest and attention. Positive transference toward the prescriber may spill over to the medication, which can be viewed as a "relationship equivalent" or gift (Gutheil 1978) .
Countertransference, or feelings and attitudes evoked in the physician by the patient, has also been described as potentially undermining pharmacotherapy. Hopelessness and frustration in the face of patient noncompliance and a desire to see the patient taught a lesson by suffering a relapse have been described as common countertransference reactions (Weiden et al. 1986; Book 1987) . The urge to abandon or humiliate the noncompliant patient may also be felt. In this respect, allowing the noncompliant patient who leaves treatment against medical advice to do so with dignity can at least set the stage for more collaborative interactions should the patient return in the future (Diamond 1983; Frances and Weiden 1987) .
Discussion
Major difficulties in empirical studies of noncompliance include both ascertainment and the fact that the most severely noncompliant individuals leave treatment altogether. Those who remain are the "curiously ambivalent" individuals who continue in care, but do not adhere to prescriptions (Blackwell 1972) . In view of these limitations it is perhaps surprising that available empirical studies yield a relatively consistent set of correlates of noncompliance in schizophrenia, as outlined in table 1.
In evaluating these findings, it is important to note that data suggest multiple possible causes of noncompliance. Because noncompliance can have many causes, its statistical association with any single factor is diluted by the presence of patients in the sample for whom other factors are causal. Similarly, the potential impact of interven- 
Health Belief Model and Differential Diagnosis of
Noncompliance. The health belief model posits that health behavior is a product of an implicit and subjective assessment of the relative costs and benefits of compliance in relation to personal goals and the constraints of everyday life. Elements of this model include (1) individual goals and priorities; (2) an evaluation of the perceived adverse effects of illness and the personal risk of suffering these effects; (3) the individual's perception of the advocated health behavior's likely effectiveness and feasibility (the patient's subjective assessment of benefits weighed against the costs of treatment, including physical, psychological, and practical disadvantages and barriers to action); and (4) the availability of internal or external cues to action that trigger health behavior (Becker and Maiman 1975; Bebbington 1995) . Because schizophrenia may disrupt illness perception and the capacity to plan and act, consideration of the cognitive and motivational resources available to assess risk and formulate action should be an additional element of a health belief model applicable to schizophrenia.
Elements of this modified health belief model outline areas of assessment pertinent to the differential diagnosis of noncompliance. A structured interview that explores Table 2 . General interventions to maximize the likelihood of compliance
• Conduct an assessment of compliance history and risk factors, including substance abuse and financial or other practical barriers, as part of the evaluation of every patient.
• Allow sufficient time to know the patient as a person and to understand his or her personal goals, concerns, and psychodynamic issues. Place assisting the patient in meeting self-defined goals at the center of treatment.
• Use a negotiated approach to medication. Create a therapeutic environment where deviation from recommendations can be discussed openly, rather than concealed. Show an interest in medication by asking in a nonauthoritarian manner how much is being taken and the effects. Involve the patient in medication treatment by allowing self-regulation of dosage, if possible.
• Maximize efficacy and minimize side effects in choosing agents and dosages. Attend seriously to all side effects and actively elicit and respond to concerns.
• Educate patient and family regarding the biological underpinnings of illness, relapse prevention, and medication side effects.
• Enlist support in the community, including family, friends, and employers. If needed, arrange for supervised medication administration.
• Employ cognitive and memory-enhancing strategies if disorganization or forgetfulness is a problem.
• When the patient is rendered incompetent because of illness, be prepared to recommend judicial intervention.
• If the patient will not comply and is competent, manage countertransference to allow for a continued relationship and the possibility of future treatment.
• Promote the patient's participation in activities that can compete with psychosis as sources of gratification and serf-esteem. many of these areas has been developed to facilitate patient evaluation (Weiden et al. 1994) .
Noncompliance may signal that patient and physician goals and priorities differ (Weiden et al. 1986 ). Maintaining sexual functioning, avoiding obesity, or not missing work for a doctor's appointment, for example, may be of primary importance to the patient, whereas relapse reduction is the physician's priority. An assessment of patient goals forms the basis of a negotiated approach to prescription that is likely to enhance compliance (Eisenthal et al. 1979; Wilson 1995) .
Since pursuing strategies designed to remedy inadvertent noncompliance will fail when noncompliance is purposeful, the differential diagnosis should attempt to separate intentional from inadvertent noncompliance. Empirical studies suggest that from the patient's perspective an immediate subjective dysphoria or other side effects are the most significant costs of compliance. Psychological reports suggest that stigma, loss of the sick role, or disturbed psychic homeostasis may be less discernible costs. These costs may weigh heavily, particularly when accompanied by a low perceived benefit of medication that derives from a lack of knowledge, poor insight, denial, or grandiosity. Interventions under such circumstances should target potentially modifiable elements thought to be operative for the individual patient. Neuroleptic dosage reductions, use of adjunctive agents, or a change to an atypical neuroleptic with fewer side effects may reduce the cost side of the equation. Promoting participation in self-esteem-enhancing activities may diminish the need to maintain delusional sources of self-esteem. Change to an agent with greater efficacy may reduce denial and grandiosity and create the potential for greater insight and perceived medication benefits.
Inadvertent noncompliance is associated whh severe psychopathology, including cognitive disorganization, memory impairment, or motivational deficits. The chaotic life circumstances associated with substance abuse comorbidity, as well as such practical considerations as finances and transportation, may also be operative. Here behavioral skill and memory-enhancing interventions, assertive outreach efforts, and recruiting the assistance of family or other supports to supervise medication are major treatment considerations.
New Neuroleptics Versus Depot Preparations.
Because of their reduced extrapyramidal side effects and greater efficacy against positive and negative symptoms, new neuroleptics, such as clozapine, risperidone, olanzapine, and sertindole, should provide greater patient benefits at a reduced perceived cost. Depot preparations have the advantage of eliminating covert noncompliance and maximizing the likelihood of steady-state neuroleptic blood levels in patients with cognitive disorganization, memory disturbance, or motivational deficits. Although an empirical basis for choosing among these two pharmacological interventions is not available, the full range of factors associated with noncompliance might be considered clinically relevant. Patients with good insight and a good therapeutic alliance but who report intolerable side effects are likely the best candidates for a trial of a new agent. Patients with poor insight, grandiosity, or other psychotic symptoms or those with memory, motivational, or cognitive deficits might also benefit from a trial of a new agent in the absence of comorbid substance abuse and the presence of either a good therapeutic alliance or adequate family or other supervision to ensure regular adherence. Poor insight and severe psychopathology in the absence of sufficient supervision favor the use of depot agents. Weiden (1995) has suggested that family factors may also have a bearing on the decision between atypical depot agents: Family concern over akinesia or other side effects favors a trial of a new agent, whereas chronic family conflict over taking oral medications favors depot preparations.
It is useful to reassess the decision between depot and new neuroleptics periodically. Some patients, for example, may require a considerable period of depot treatment to attain a level of clinical stability, therapeutic alliance, and insight sufficient to render a trial of a new agent feasible.
Conclusion
The prevention and treatment of noncompliance are of major importance in the care of patients with schizophrenia. Although noncompliance has multiple causes, the empirical literature identifies a circumscribed set of factors that alone or in varying combinations are likely to be operative in individual cases. Exploring each of these factors within a modified health belief model should allow for differential diagnosis and an individualized approach to reducing noncompliance. A comprehensive understanding and integration of patient, illness, treatment, and environmental factors are needed to manage noncompliance (Kane 1986 ). This integrated approach can best be accomplished within an ongoing physician-patient relationship that allows sufficient time for doctor and patient to know each other and maintain a collaborative therapeutic association over time (Fenton and McGlashan 1995) .
